Vida Ventures

Founded 2017
Founders Arie Belldegrun Arjun Goyal Fred Cohen Len Potter Stefan Vitorovic

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 31
Average round size
info
The average size of a deal this fund participated in
$90M
Portfolio companies 27
Rounds per year 7.75
Lead investments 8
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.16
Exits 10
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical
Summary

In 2017 was created Vida Ventures, which is appeared as VC. The venture was found in North America in United States. The leading representative office of defined VC is situated in the Boston.

This organization was formed by Arjun Goyal, Len Potter, Stefan Vitorovic. Besides them, we counted 4 critical employees of this fund in our database.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Vida Ventures, startups are often financed by SV Health Investors, Skyline Ventures, Amgen Ventures. The meaningful sponsors for the fund in investment in the same round are Nextech Invest, OrbiMed, The Column Group. In the next rounds fund is usually obtained by Perceptive Advisors, Nextech Invest, venBio Select Advisor.

Among the most popular portfolio startups of the fund, we may highlight Allogene Therapeutics, Pionyr Immunotherapeutics, Kronos Bio. The fund has no exact preference in some founders of portfolio startups. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Biotechnology, Medical Device. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

The important activity for fund was in 2019. The fund is generally included in 2-6 deals every year. The common things for fund are deals in the range of more than 100 millions dollars. Speaking about the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. The increased amount of exits for fund were in 2018. This Vida Ventures works on 4 percentage points more the average amount of lead investments comparing to the other organizations.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Vigil Neuroscience

Biotechnology
$90M18 Aug 2021 Cambridge, Massachusetts, United States

Tectonic Therapeutic

Biotechnology
$80M15 Apr 2021 Boston, Massachusetts, United States

Biotechnology
Medical
$32M06 Apr 2021 New York, New York, United States

Aktis Oncology

Biotechnology
Life Science
$72M18 Mar 2021 Boston, Massachusetts, United States

Scorpion Therapeutics

Biotechnology
Health Care
Life Science
$162M07 Jan 2021 Boston, Massachusetts, United States

Biotechnology
$77M05 Jan 2021 San Diego, California, United States

Biotechnology
Health Care
Therapeutics
$100M14 Dec 2020 San Diego, California, United States

Scorpion Therapeutics

Biotechnology
Health Care
Life Science
$108M26 Oct 2020 Boston, Massachusetts, United States

A2 Biotherapeutics

Biotechnology
Life Science
$71M06 Oct 2020 California, United States
News
ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million

– ReCode Therapeutics announced the closing of an $80m Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.
– The round was led by Pfizer Ventures and EcoR1 Capital.
– New investors include Sanofi Ventures, funds managed by Tekla Capital Management, Superstring Capital and NS Investment.
– Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, and Osage University Partners.

Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases

– Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced the completion of a $90m Series B financing to further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration.
– The financing was led by Vida Ventures with participation from existing investors Atlas Venture, Northpond Ventures and Hatteras Venture Partners as well as new investors including Surveyor Capital (a Citadel company), Cormorant Asset Management, Invus, OrbiMed, Rock Springs Capital, Deep Track Capital, Logos Capital, Pivotal bioVenture Partners, and Lightstone Ventures.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Vida Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: